PharmaShots | Incisive News in 3 Shots

Subscribe Now

China

Innovent Entered into a Collaboration Agreement with NeoCura to Evaluate Sintilimab + NEO_PLIN2101 for Cancer in China

Innovent Entered into a Collaboration Agreement with NeoCura to Evaluate Sintilimab + NEO_PLIN2101 for Cancer in China

October 28, 2021

Hutchmed Initiates P-III ESLIM-01 Trial of HMPL-523 for the Treatment of Immune Thrombocytopenia in China

Hutchmed Initiates P-III ESLIM-01 Trial of HMPL-523 for the Treatment of Immune Thrombocytopenia in China

October 28, 2021

AstraZeneca and Hutchmed Initiate P-III SANOVO Trial for Orpathys (savolitinib) + Tagrisso (osimertinib) as a 1L Therapy for Non-small Cell Lung Cancer in China

AstraZeneca and Hutchmed Initiate P-III SANOVO Trial for Orpathys (savolitinib) + Tagrisso (osimertinib) as a 1L Therapy for Non-s...

September 9, 2021

BeiGene Reports NMPA's Acceptance of sBLA for Tislelizumab (BGB-A317) to Treat Nasopharyngeal Cancer in China

BeiGene Reports NMPA's Acceptance of sBLA for Tislelizumab (BGB-A317) to Treat Nasopharyngeal Cancer in China

August 23, 2021

Novartis' Cosentyx (secukinumab) Receives the NMPA's Approval for the Treatment of Pediatric Psoriasis in China

Novartis' Cosentyx (secukinumab) Receives the NMPA's Approval for the Treatment of Pediatric Psoriasis in China

August 17, 2021

Mabpharm's Biobetter (CMAB008) for Infliximab Receives NMPA's Approval in China

Mabpharm's Biobetter (CMAB008) for Infliximab Receives NMPA's Approval in China

July 22, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us